前列腺癌：在去势抵抗性疾病中增加比卡鲁胺剂量。 - Suppr

Suppr

超能文献

Prostate cancer: Bicalutamide dose increase in castration-resistant disease.

作者信息

Labrie Fernand

机构信息

Laval University, 2795 Laurier Boulevard, Suite 500, Quebec City, QC G1V 4M7, Canada.

出版信息

Nat Rev Urol. 2015 Mar;12(3):132-3. doi: 10.1038/nrurol.2014.334. Epub 2014 Dec 9.

DOI:10.1038/nrurol.2014.334

PMID:25487048

Abstract

摘要

相似文献

Prostate cancer: Bicalutamide dose increase in castration-resistant disease.

Nat Rev Urol. 2015 Mar;12(3):132-3. doi: 10.1038/nrurol.2014.334. Epub 2014 Dec 9.

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

Urology. 2010 Nov;76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. Epub 2010 Mar 29.

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

Urology. 1995 Dec;46(6):849-55. doi: 10.1016/S0090-4295(99)80356-2.

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs. 2006;66(6):837-50. doi: 10.2165/00003495-200666060-00007.

The third analysis of the bicalutamide Early Prostate Cancer programme.

BJU Int. 2006 Mar;97(3):438-9. doi: 10.1111/j.1464-410X.2006.06118.x.

[The role of bicalutamide in the treatment of prostate cancer].

Harefuah. 2002 Apr;141(4):379-83, 408, 407.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.

Eur J Cancer. 2015 Aug;51(12):1555-69. doi: 10.1016/j.ejca.2015.04.028. Epub 2015 Jun 2.

[Bicalutamide].

Nihon Rinsho. 2000 Jul;58 Suppl:216-22.

[A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].

Gan To Kagaku Ryoho. 1999 Jul;26(8):1201-7.

引用本文的文献

Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.

Nat Rev Urol. 2023 Aug;20(8):480-493. doi: 10.1038/s41585-023-00726-1. Epub 2023 Feb 14.

Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Int Urol Nephrol. 2015 Mar;47(3):479-84. doi: 10.1007/s11255-015-0919-y. Epub 2015 Feb 10.

本文引用的文献

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4. doi: 10.1038/pcan.2014.24. Epub 2014 Sep 2.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.

The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

J Urol. 2006 Dec;176(6 Pt 2):S47-9. doi: 10.1016/j.juro.2006.06.070.

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.

Lancet. 2000 Apr 29;355(9214):1491-8.

Estimated potency of Casodex: a problematic design.

Urology. 1997 Aug;50(2):309-13.

Clinical progress with a new antiandrogen, Casodex (bicalutamide).

Eur Urol. 1996;29 Suppl 2:96-104. doi: 10.1159/000473847.

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

Urology. 1996 Jan;47(1A Suppl):38-43; discussion 48-53. doi: 10.1016/s0090-4295(96)80007-0.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

Urology. 1995 May;45(5):745-52. doi: 10.1016/s0090-4295(99)80077-6.

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

Clin Invest Med. 1982;5(4):267-75.

Benefits of combination therapy with flutamide in patients relapsing after castration.

Br J Urol. 1988 Apr;61(4):341-6. doi: 10.1111/j.1464-410x.1988.tb13971.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验